Literature DB >> 32776432

Characterization of adipose-derived stromal/stem cell spheroids versus single-cell suspension in cell survival and arrest of osteoarthritis progression.

Ji-Yun Ko1, Jeong-Won Park1, Juyoung Kim1, Gun-Il Im1,2.   

Abstract

The current study evaluated the hypothesis that the administration of spheroidal adipose-derived stromal/stem cells (ASCs) promotes cell survival and arrests the progression of surgically induced osteoarthritis (OA) in a rat model. We also tested the optimal conditions for spheroid production from ASCs using microwell methods. The formation of ASC spheroids was optimized at a well diameter of 600 μm under cell concentrations of 106 cell/ml. When ASC spheroids cultured in 3D were compared with ASCs cultured in 2D monolayer, the cell survival and chondrogenic potential were enhanced while the apoptosis was reduced in ASC spheroids compared with ASCs in 2D monolayer culture. In vivo tracking of fluorescently labeled ASCs in the knee joints of rats with surgically induced OA showed longer fluorescent activity at a higher intensity in ASC spheroids than in ASC single-cell suspension. When OA-induced rats treated with ASC injection were sacrificed after 8 weeks, the OARSI score was enhanced in both ASC single-cell suspension and ASC spheroids compared with negative control, spheroid treatment resulting in a better score than single-cell treatment. However, injected cells were not detectable from the joints. These finding altogether suggests that ASC spheroids have better in vitro and in vivo survival and chondrogenic potential and exert greater regenerative effects for articular cartilage and arrest the progression of surgically induced OA better than ASCs in single-cell suspension by the paracrine mode of action. The study findings support the notion of developing cell therapeutics to treat OA based on ASC spheroid forms.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  adipose-derived stromal/stem cells; articular cartilage; chondrogenesis; osteoarthritis; spheroid

Mesh:

Substances:

Year:  2020        PMID: 32776432     DOI: 10.1002/jbm.a.37078

Source DB:  PubMed          Journal:  J Biomed Mater Res A        ISSN: 1549-3296            Impact factor:   4.396


  5 in total

Review 1.  Cell-based therapies have disease-modifying effects on osteoarthritis in animal models. A systematic review by the ESSKA Orthobiologic Initiative. Part 1: adipose tissue-derived cell-based injectable therapies.

Authors:  Carlotta Perucca Orfei; Angelo Boffa; Yosef Sourugeon; Lior Laver; Jérémy Magalon; Mikel Sánchez; Thomas Tischer; Giuseppe Filardo; Laura de Girolamo
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2022-09-14       Impact factor: 4.114

2.  Emerging Concepts of Endotypes/Phenotypes in Regenerative Medicine for Osteoarthritis.

Authors:  Gun-Il Im; Jae-Yeon Moon
Journal:  Tissue Eng Regen Med       Date:  2021-10-21       Impact factor: 4.451

3.  Metformin Ameliorates Senescence of Adipose-Derived Mesenchymal Stem Cells and Attenuates Osteoarthritis Progression via the AMPK-Dependent Autophagy Pathway.

Authors:  Zheng Li; Lin Liu; Yanni Yang; Haishi Zheng; Yongsong Cai; Yao Ma; Ruiying Gu; Ke Xu; Rui Zhang; Peng Xu
Journal:  Oxid Med Cell Longev       Date:  2022-06-03       Impact factor: 7.310

4.  Evaluation of the Usefulness of Human Adipose-Derived Stem Cell Spheroids Formed Using SphereRing® and the Lethal Damage Sensitivity to Synovial Fluid In Vitro.

Authors:  Atsushi Fuku; Yasuhiko Taki; Yuka Nakamura; Hironori Kitajima; Takashi Takaki; Terutsugu Koya; Ikuhiro Tanida; Kaori Nozaki; Hiroshi Sunami; Hiroaki Hirata; Yoshiyuki Tachi; Togen Masauji; Naoki Yamamoto; Yasuhito Ishigaki; Shigetaka Shimodaira; Yusuke Shimizu; Toru Ichiseki; Ayumi Kaneuji; Satoshi Osawa; Norio Kawahara
Journal:  Cells       Date:  2022-01-20       Impact factor: 6.600

Review 5.  Biomaterials-assisted spheroid engineering for regenerative therapy.

Authors:  Na-Hyun Lee; Oyunchimeg Bayaraa; Zhou Zechu; Hye Sung Kim
Journal:  BMB Rep       Date:  2021-07       Impact factor: 4.778

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.